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Abstract
Background: Chronic kidney disease (CKD) is a global public health problem that disproportionally affects people
of African ethnicity. We assessed the prevalence and determinants of CKD and albuminuria in urban and rural
adults Cameroonians.
Methods: This was a cross-sectional study of 6-month duration (February to July 2014), conducted in the health
district of Dschang (Western Region of Cameroon), using a multistage cluster sampling. All adults diagnosed with
albuminuria (≥30 mg/g) and/or decreased estimated glomerular filtration rate (eGFR) (<60 ml/min/1.73 m2) were
re-examined three months later. Logistic regression models were used to relate baseline characteristics with
prevalent CKD.
Results: We included 439 participants with a mean age of 47 ± 16.1 years; with 185 (42.1 %) being men and 119
(27.1 %) being urban dwellers. There was a high prevalence of hypertension (25.5 %), diabetes (9.8 %), smoking
(9.3 %), alcohol consumption (59.7 %), longstanding use of herbal medicine (90.9 %) and street medications
(87.5 %), and overweight/obesity (53.3 %) which were predominant in rural area. The prevalence of CKD was 13.2 %
overall, 14.1 % in rural and 10.9 % in urban participants. Equivalents figures for CKD stages G3-G4 and albuminuria
were 2.5 %, 1.6 % and 5.0 %; and 12.1 %, 14.1 % and 6.7 % respectively. Existing hypertension and diabetes were
associated with all outcomes. Elevated systolic blood pressure and the presence of hypertension and diabetes were
the predictors of albuminuria and CKD while urban residence was associated with CKD stages G3-G4.
Conclusion: The prevalence of CKD and albuminuria was high in this population, predominantly in rural area, and
driven mostly by the commonest risk factors.
Background
Chronic kidney disease (CKD) affects about 1 in 10
adults and accounts for millions of premature deaths
worldwide [1, 2]. Studies have revealed that people of
African ethnicity are at higher risk of CKD, which is
credited to be 3–4 times more frequent in Africans than
in developed countries [3]. Many Sub-Saharan Africa
(SSA) countries are going through epidemiological tran-
sitions and are confronted with the double burden of
communicable and non-communicable diseases includ-
ing CKD [3–5]. However, the few epidemiological stud-
ies conducted in SSA have revealed huge disparities in
the prevalence of CKD in the adult population, with fig-
ures ranging from 1.5 to 38 % depending on methods
used to diagnose CKD and population characteristics
[6–12]. Furthermore, CKD in SSA tend to affect mostly
young adults, with hypertension, chronic glomerulo-
nephritis, diabetes, HIV infection, obesity and herbal
medicines use being the main potential contributing fac-
tors [3, 5, 7, 8, 10, 11].
High prevalence of CKD have been reported in Central
African countries [7, 8, 12]. However, existing studies have
been based on non-optimal definition of CKD using a sin-
gle measurement; which is at variance with the 2012
KDIGO guidelines recommendations of using at least two
measurements three months apart [13]. As such, available
studies have likely provided inaccurate estimates of the dis-
ease burden. In the absence of data on the epidemiology of
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chronic kidney disease in Cameroon, we undertook this
study to establish the prevalence and investigate the
determinants of CKD in rural and urban settings in the
country.
Methods
Study design and setting
This was a cross-sectional study of 6-month duration
(February to July 2014), conducted in the health district
Dschang in the Western Region of Cameroon (Fig. 1).
Study participants
Sources of participants
According to the data from the regional delegation of
health for the Western Region of Cameroon, Dschang
health district is the largest health district in the region,
with an estimated population of 309,285 inhabitants in
2012, distributed across 22 health areas (19 rurals and 3
urbans) (2012 annual activity report of the regional dele-
gation of health for Western Cameroon). Dschang is
home to the largest university in the Region and there-
fore has a cosmopolitan population reflecting the ethnic
diversity of the country. The adult population in urban
areas comprises students, traders, civil servants and mid-
dle income earners from private sectors while farmers
are predominant in rural area. This study was approved
by the Cameroon National Ethics Committee, and all
participants provided a written informed consent before
enrolment.
Eligibility criteria
Eligible participants were adults aged 20 years and above
who had been living in the study setting for more than
three months. We excluded individuals with serious
mental or physical (limb amputation or paralysis) dis-
ability, pregnant or breastfeeding women and partici-
pants with simultaneous leucocyturia and urine nitrites.
Selection of participants
We used a multi-level cluster sampling including the
health area (first level), the village (second level), the
neighbourhood (third level) and the household (fourth
level). The sequence below was followed to select the clus-
ters and corresponding health areas. 1) We first assumed
the number of clusters needed to be 30; 2) We then deter-
mined the sampling interval (SI) which corresponded to
10310, by dividing the population of Dschang health
district by the number of clusters; 3) We determined the
first cluster or random number (RN) by selecting the four












Fig. 1 Dschang district in the Western Region of Cameroon
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corresponded to 1399; 4) We next estimated the cluster
number size (C(n)) from the formula C(n) = RN+(n-1)*SI
where n is the cluster number; 5) The various health areas
(with their corresponding population size) were then
sorted in alphabetic order and progressive cumulative
population size estimated (see Additional file 1: Table S1);
6) The last step consisted of selecting the health areas. For
a health area to be selected, the size of the corresponding
cluster number had to be less than the health area popula-
tion. This action was repeated until the size of the cluster
number became superior to the health area population;
we then moved to the following health area in the table.
The selected health areas and corresponding clusters are
presented in Additional file 1: Table S1.
In a selected health area, one village/neighbourhood was
randomly drawn when there was more than one regardless
of the population size. The starting point was randomly se-
lected from the market, church, health centre or school in
the village/neighbourhood. Thereafter, we randomly se-
lected the direction while the side of road was chosen with
the aid of coin toss. We entered consecutively in the
households where we randomly selected per household a
maximum of two adults aged 20 years and above among
those who had been living in the household for more than
three months. For each household declining to participate,
the next household was selected until the total number re-
quired for the cluster size was reached. The cluster size
ranged between 14 and 15 subjects. In health areas with
many clusters, the corresponding villages and/or neigh-
bourhoods were randomly selected as previously described.
Variables of interest
The main outcome of interest in this study was CKD de-
fined by the persistence after 3 months of albuminuria
(Albumin/Creatinine ratio ≥ 30 mg/g) and/or decreased
estimated glomerular filtration rate (eGFR) (<60 ml/min/
1.73 m2) according to the K/DIGO guidelines [13]. Expos-
ure variables included demographics (age and gender),
self-reported existing conditions (hypertension, diabetes
and gout), any hypertension (self-reported or screen-de-
tected [i.e. systolic (or diastolic) blood pressure ≥140
(90)], any diabetes (self-reported or screen-detected
[fasting capillary glucose ≥126 mg/dl)], lifestyles (alcohol
consumption and smoking), use of nephrotoxins [street
medications (western drugs, usually of uncertain origins
that are sold in shops and regularly along market streets,
instead of pharmacies, and without any control) and
herbal medicines], overweight or obesity (body mass index
[BMI] ≥ 25 kg/m2) and blood pressure levels. Potential ef-
fect modifier was residency (urban vs. rural).
Data sources and measurement
Data were collected during household surveys by final
year’s undergraduate medical students. Demographics,
history of existing conditions, lifestyles and data on the
use of nephrotoxins were collected during face-to-face in-
terviews with participants. Blood pressure was measured
according to the World Health Organization (WHO)
guidelines [14] using an automated sphygmomanometer
(OMRON HEM705CP, Omron Matsusaka Co, Matsusaka
City, Mie-Ken, Japan) on the right arm with participants
in a sitting position after 30 min of rest with a cuff size of
23 x 12 cm or larger for obese individuals. Body weight
and height were measured three times and their average
used in all analyses. For each participant, 3 ml of whole
blood was collected from an antecubital vein for serum
creatinine and fasting glycemia (after an overnight fast of
at least 8 h), and mid-stream second morning urine col-
lected for dipstick, creatinine and albumin tests. Fasting
glycemia and dipstick tests were done immediately after
sample collection. The remaining sample was transported
in ice to the Biochemistry Laboratory of the Yaounde
University Teaching Hospital for further processing.
Urine dipstick tests used the CombiScreen 7SL PLUS 7
test strips (Analyticon Biotechnologies AG, D-35104
Lichentenfeis, Germany). Fasting glycemia was per-
formed using One Touch Ultra® easy reader® (LifeScan
Europe, Cilag GmbH International, Zug, Switzerland).
Serum and urinary creatinine were measured with a
kinetic modification of the Jaffé reaction using Human
visual spectrophotometer (Human Gesellschaft, Bio-
chemica und Diagnostica mbH, Wiesbaden, Germany)
and Beckman creatinine analyzer (Beckman CX systems
instruments, Anaheim, CA, USA) while urinary albu-
min was measured using pyrogallol red-molybdate
complex with Teco diagnostics tests (Teco Diagnostics,
Anaheim, CA, USA). For any participant with positive
dipstick [proteine (≥ trace), blood, leucocytes), albu-
min/creatinine ratio (ACR) ≥30 mg/g and fasting gly-
cemia of at least 126 mg/dl (for unknown diabetes),
another test was performed 2 to 3 weeks after to con-
firm the results. In participants with estimated glom-
erular filtration rate (eGFR) < 60 ml/min/1.73 m2
according to the MDRD formula and/or urinary albu-
min/creatinine ratio (ACR) ≥30 mg/g, the chronicity
was confirmed on another sample 3 months later.
Definitions and calculations
Estimated glomerular filtration rate (eGFR, ml/min) corre-
sponded to creatinine clearance. For the main analyses,
eGFR was based on the four-variable MDRD (Modifica-
tion of Diet in Renal Disease) study equation; however, for
comparison purpose of the baseline estimates, we also de-
rived the eGFR from the Cockcroft–Gault (CG) formula
and the CKD-EPI (Chronic Kidney Disease Epidemiology
Collaboration) equations [15–17]. 24-h albuminuria was
estimated from Albumin/Creatinine ratio (mg/g). BMI
was estimated as weight (kg)/height (m)*height (m).
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Study size
By considering a 10 % prevalence (P) of CKD in adults
[1], a precision (I) of 2 %, a correction factor (K) of 2 for
the cluster effect, a 95 % confidence interval, the min-
imal sample size (N) required was 432 subjects using the
following formula N = [(Zα /2)2 PQ/ I2] x K.
Handling of quantitative variables
Age was treated as continuous variable in all analysis
while blood pressure, while other quantitative variables
were treated both as continuous and categorical variables,
based on clinically meaningful stratification. Hypertension
was defined as a systolic (SBP) ≥140 mmHg and/or a dia-
stolic blood pressure (DBP) ≥90 mmHg or use of blood
pressure lowering medications. Diabetes mellitus was de-
fined as repeated fasting glycemia ≥ 126 mg/dl or use of
glucose control agents. A BMI > 25 kg/m2 was used to de-
fine overweight and obesity. CKD was classified based on
GFR and albuminuria categories. GFR categories of CKD
included: G1 (eGFR ≥ 90); G2 (eGFR 60–89); G3a (eGFR
45–59); G3b (eGFR 30–44); G4 (eGFR 15–29) and G5
(eGFR < 15). Albuminuria categories of CKD were: A1
(<30 mg/g); A2 (30–300 mg/g) and A3 (>300 mg/g). The
following formula was used to convert serum creatinine
from Jaffe reaction (SCrJaffe) to standardized serum cre-
atinine (SCrStandardized) for use in MDRD and CKD-EPI
formulas: SCrStandardized = 0.95*SCrJaffe – 0.10 [18].
Statistical analysis
Data analysis used SAS/STAT v9.1 software and the sur-
vey analysis procedures (‘proc surveymeans’, ‘proc sur-
veyreg’ and ‘proc surveylogistic’) to account for the
multilevel sampling design of the study. We have reported
the results as means, counts and percentages and the ac-
companying 95 % confidence intervals. The sampling
error was estimated with the use of the Taylor expansion
method. Age and sex adjusted logistic regression models
were used to investigate the predictors of CKD, CKD
stages G3-G4 and albuminuria. A p-value <0.05 was used
to indicate statistically significant results. For the main
analyses, prevalence and determinants of CKD are based
on MDRD derived eGFR. In secondary analyses however,
we have also estimated GFR and staged kidney function
using the Cockroft-Gault and CKD-EPI equations.
Results
Baseline characteristics of the study population
A total of 238 households were included in the survey
from which 439 subjects (two participants from 201
households and one participant from the remaining) par-
ticipated in the study. Eleven (2.5 %) participants from
seven (2.9 %) households refused to participate. These
households were replaced as described above. The rea-
sons for non-participation were fear (3 participants, 2
households), absence from home after several visits (2
participants, 2 households) and lack of time due to work
constraints (6 participants, 3 households).
We included 439 participants aged 47 ± 16.1 years,
with 185 (42.1 %) being men and 119 (27.1 %) being
urban dweller. In all, 120 (27.3 %) participants had renal
abnormalities requiring repeated tests to confirm the
chronicity, including 73 (60.8 %) with only albuminuria
(ACR ≥ 30 mg/g), 34 (28.3 %) with only decreased eGFR
(<60 ml/min/1.73 m2) and 13 (10.8 %) with both. The
chronicity confirmation test was not performed in 6
(5.3 %) participants including 1 (1.4 %) for albuminuria,
3 (10.3 %) for decreased eGFR and 2 (18.2 %) for both.
Reasons for not performing the tests were death (one
case) and hospitalisation (5 cases) in other cities for
medical care. They were all considered as having nega-
tive confirmation tests.
As presented in Table 1, we noticed a high proportion
of participants who were unaware of their status for
renal disease (80.9 %), hypertension (33 %), diabetes
(42.6 %) and gout (56.3 %). There was also a high preva-
lence of CKD related risk factors in this setting including
hypertension (25.5 %), diabetes (9.8 %), smoking (9.3 %),
alcohol consumption (59.7 %), longstanding use of herbal
medicines (90.9 %) and street medications (87.5 %), and
overweight/obesity (53.3 %). This population presented
a high prevalence of dipstick proteinuria (19.6 %) and
decreased eGFR at 10.7 % based on the MDRD equa-
tion, Table 2.
Compared with their urban counterparts, rural partici-
pants were older (51.0 vs. 36.5 years, p < 0.001) and less
aware of their status for renal disease, hypertension, dia-
betes and gout (all p < 0.001), Table 1. Furthermore, they
included higher proportion of alcohol drinkers, longstand-
ing users of street and herbal medicine, and had elevated
SBP and waist girth, and higher prevalence of hyperten-
sion and albuminuria (all p ≤ 0.021), Tables 1 and 2. The
prevalence of combined albuminuria and/or decreased
MDRD-based eGFR was 30 % (95 % CI: 24.3-46.7) in rural
and 20.2 % (8.3-32.0) in urban areas (p = 0.162), Table 2.
There were suggestions that urban vs. rural variations
in the levels of some characteristics occurred in differ-
ential ways between men and women. This was the
case for age, tobacco use, alcohol use, body mass index,
eGFR and prevalent CKD (all p < 0.037 for sex*resi-
dence interactions), Tables 1 and 2.
Prevalence and correlates of albuminuria and chronic
kidney disease
As presented in Table 3, the prevalence of albuminuria was
12.1 % (n = 53) overall, 14.1 % (n = 45) in rural and 6.7 %
(n = 8) in urban participants (p = 0.047). Compared with
their non-albuminuric counterparts, participants with al-
buminuria had higher prevalence of existing hypertension
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(p < 0.0001), diabetes (p < 0.003), gout (p = 0.0002) and
longstanding use of herbal medicine (p = 0.0001),
higher SBP (p = 0.019), and higher prevalence of any
hypertension (p = 0.0001) and diabetes (p = 0.008). The
prevalence of CKD was 13.2 % with 2.5 % at stages G3-
G4, Table 3. Equivalents figures were 14.1 % and 1.6 %
in rural, and 10.9 % and 5.0 % in urban participants. CKD
was associated with history of hypertension (p = 0.001),
diabetes (p = 0.017) and gout (p = 0.009), herbal medicines
(p < 0.0001) and street medications (p = 0.007) use, any
diabetes (p = 0.017) and hypertension (p < 0.0001),
while stages G3-G4 of CKD were associated with fe-
male sex (p < 0.0001), tobacco use (p < 0.0001), and herbal
medicines (p < 0.0001) and street medications (p < 0.0001)
use, Table 3. In males vs. female comparisons, the preva-
lence of albuminuria was 10.3 % and 13.4 % respectively.
Equivalents figures were 10.3 % and 15.3 % for CKD, and
0 % and 4.3 % for stages G3-G4 of CKD.
Predictors of albuminuria and chronic kidney disease in
age, sex and residency adjusted logistic regressions
Existing hypertension and diabetes were consistently and
positively associated with higher risk of all outcomes with
however, borderline association between hypertension and
stages G3-G4 CKD (p = 0.056), Table 4. Elevated SBP and
the presence of hypertension and diabetes were the pre-
dictors of albuminuria and CKD. Rural residence was
negatively and consistently associated with the presence of
Table 1 Baseline clinical characteristics by sex and urban/rural location
Characteristics Overall Rural Urban p p sex*residence
n (%) 439 (100) 320 (72.9) 119 (27.1)
Mean age, years (95 % CI) 47.0 (42.5-51.6) 51.0 (49.1-52.9) 36.5 (32.6-40.3) <0.0001 0.007
Men, n; % (95 % CI) 185; 42.1 (35.6-48.7) 127; 39.7 (33.0-46.4) 58; 48.7 (37.3-60.2) 0.154 NA
History of renal disease, n; % (95 % CI) <0.0001 0.640
Yes 1; 0.2 (0.0-0.7) 0 1; 0.8 (0.0-1.7)
No 83; 18.9 (0.0-38.1) 12; 3.8 (1.9-5.6) 71; 59.7 (38.7-80.6)
Don’t know 355; 80.9 (61.3-100.0) 308; 96.2 (94.4-98.1) 47; 39.5 (17.8-61.1)
History of hypertension, n; % (95 % CI) <0.0001 0.712
Yes 47; 10.7 (8.3-13.1) 33; 10.3 (7.3-13.3) 14; 11.8 (9.7-13.8)
No 247; 56.3 (46.5-66.1) 148; 46.3 (43.9-48.5) 99; 83.2 (76.6-89.7)
Don’t know 145; 33.0 (22.4-43.6) 139; 43.4 (40.4-46.4) 6; 5.0 (0.0-11.8)
History of diabetes, n; % (95 % CI) <0.001 0.835
Yes 26; 5.9 (2.7-9.1) 23; 7.2 (3.8-10.5) 3; 2.5 (0.0-6.6)
No 226; 51.5 (38.3-64.7) 122; 38.1 (35.0-41.3) 104; 87.4 (81.2-93.6)
Don’t know 187; 42.6 (31.1-54.1) 175; 54.7 (51.6-57.8) 12; 10.1 (6.0-14.2)
History of gout, n; % (95 % CI) <0.001 0.063
Yes 5; 1.1 (0.6-1.7) 4; 1.3 (0.6-1.9) 1; 0.8 (0.0-1.7)
No 187; 42.6 (26.6-58.6) 84; 26.3 (22.8-29.7) 103; 86.6 (80.5-92.6)
Don’t know 247; 56.3 (40.2-72.3) 232; 72.5 (69.0-76.0) 15; 12.6 (6.2-19.0)
Tobacco use currently or formerly, n; % (95 % CI) 41; 9.3 (7.5-11.2) 34; 10.6 (8.5-12.7) 7; 5.9 (4.5-7.3) <0.0001 0.009
Alcohol use currently or formerly, n; % (95 % CI) 262; 59.7 (51.3-68.1) 211; 65.9 (60.7-71.1) 51; 42.9 (27.6-58.1) 0.003 0.001
Longstanding use of herbal medicine, n; % (95 % CI) 399; 90.9 (83.8-97.9) 312; 97.5 (96.1-98.9) 87; 73.1 (65.6-80.6) <0.0001 0.090
Longstanding use of street medications, n; % (95 % CI) 384; 87.5 (77.3-97.7) 306; 95.6 (93.9-97.4) 78; 65.5 (51.6-79.4) <0.0001 0.064
Mean systolic blood pressure, mmHg (95 % CI) 119.5 (117.0-122.1) 121.2 (119.5-122.9) 115.0 (111.6-118.5) 0.015 0.163
Mean diastolic blood pressure, mmHg (95 % CI) 77.9 (77.0-78.9) 78.1 (77.0-79.3) 77.4 (76.0-78.8) 0.543 0.253
Any hypertension, n (%) 112; 25.5 (22.3-28.7) 92; 28.8 (25.7-31.8) 20; 16.8 (13.0-20.6) <0.0001 0.077
Mean body mass index, kg/m2 (95 % CI) 26.0 (25.7-26.4) 26.0 (25.6-26.4) 26.2 (25.5-26.8) 0.711 0.004
BMI≥ 25, n; % (95 % CI) 234; 53.3 (49.5-57.1) 169; 52.8 (49.5-56.1) 65; 54.6 (45.6-63.6) 0.696 0.102
Mean waist girth, cm (95 % CI) 88.4 (87.2-89.7) 89.2 (88.0-90.4) 86.3 (84.8-87.9) 0.021 0.277
Mean fasting glycemia, g/l (95 % CI) 0.92 (0.88-0.96) 0.93 (0.88-0.97) 0.91 (0.87-0.95) 0.539 0.387
Any diabetes, n; % (95 % CI) 43; 9.8 (6.6-13.0) 34; 10.6 (7.2-14.0) 9; 7.6 (2.1-13.1) 0.370 0.976
95 % CI 95 % confidence intervals
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stages G3-G4 CKD while age and sex did not affect any of
the outcomes, Table 4.
Secondary analyses
The staging of kidney function and the prevalence of
any Albuminuria (≥30 mg/g) and/or eGFR (<60 ml/min/
1.73 m2) at baseline based on Cockroft-Gault (CG) and
CKD-EPI equations are shown in Table 2. Mean eGFR
was lower based on CG and higher based on CKD-EPI,
consistently in urban and rural areas, with significant
sex differential in the distribution of eGFR across areas
(both p ≤ 0.0003 for sex*residency interactions). The
overall prevalence of decreased eGFR (<60 ml/min) was
21.9 % (95 % CI: 16.3-27.4) based on CG and 10.9 %
(5.4-16.4) based on CKD-EPI, similarly in urban and rural
areas (both p ≥ 0.242), with no evidence of sex*residence
interactions (both p ≥ 0.09). The prevalence of the com-
bined albuminuria and/or decreased eGFR was 35.8 %
(27.3-44.2 %) based on CG, and 27.6 % (20.6-34.5) based
on CKD-EPI. There was no rural vs. urban differences
(both p ≥ 0.072); but there was evidence of significant inter-
actions between gender and residence for both prevalence
(both p ≤ 0.022 for sex*residence interaction), Tables 2.
Discussion
This study revealed an overall high prevalence of CKD in-
cluding albuminuria and stages G3-G4 as well as their re-
lated risk factors in this population, predominantly in the
rural area, regardless the age and sex of participants. CKD
and albuminuria were associated with history of hyperten-
sion and diabetes, elevated SBP and the presence of hyper-
tension and diabetes, whereas existing diabetes and
hypertension, and urban residency predicted the presence
of stages G3-G4 CKD.
The high prevalence of CKD observed in this popula-
tion has been reported in similar proportions in previous
Table 2 Baseline kidney function test and urine profile by location
Characteristics Overall Rural Urban p p sex*residence
n (%) 439 (100) 320 (72.9) 119 (27.1)
Dipstick abnormalities, n; % (95 % CI)
Proteinuria 86; 19.6 (13.5-25.6) 76; 23.8 (18.5-29.0) 10; 8.4 (3.3-13.5) 0.0005 0.155
Leucocyturia 22; 5.0 (2.4-7.6) 10; 3.1 (1.6-4.7) 12; 10.1 (0.0-20.1) 0.034 0.807
Hematuria 2; 0.5 (0.0-1.1) 0 2; 1.7 (0.2-3.2) <0.0001 0.984
Albuminuria, mg/g, n; % (95 % CI) 0.0004 0.148
<30 353; 80.4 (74.3-86.5) 244; 76.3 (71.0-81.5) 109; 91.6 (86.5-96.7)
30-300 70; 15.9 (10.0-21.8) 64; 20.0 (15.6-24.3) 6; 5.0 (0.0-11.1)
>300 16; 3.6 (2.1-5.2) 12; 3.8 (1.9-5.6) 4; 3.4 (1.1-5.6)
Mean serum creatinine, mg/l (95 % CI) 10.6 (10.0-11.2) 10.3; 4.9 (9.6-10.9) 11.6; 3.9 (10.5-12.8) 0.065 0.037
Mean eGFR, ml/min (95 % CI)
MDRD 109.5 (104.0-115.0) 110.9; 38.2 (105.2-116.5) 105.8; 48.1 (91.7-119.8) 0.522 0.0005
CKD-EPI 106.4 (101.3-111.5) 107.2; 30.1 (102.6-111.8) 104.2; 38.6 (90.1-118.3) 0.622 0.0003
CG 89.1 (83.2-95.0) 88.2; 35.5 (83.1-93.2) 91.8; 35.4 (78.4-105.1) 0.691 0.0002
Stages of kidney function by eGFR, n; % (95 % CI)
MDRD (ml/min/1.73 m2) >90 303; 69.0 (63.3-74.7) 238; 74.4 (70.4-78.3) 65; 54.6 (38.3-70.9) 0.2681 0.711
60-90 89; 20.3 (15.0-25.5) 53; 16.6 (13.1-20.0) 36; 30.3 (16.7-43.8)
<60 47; 10.7 (5.4-16.0) 29; 9.1 (3.0-15.1) 18; 15.1 (4.5-25.8)
CG (ml/min) >90 197; 44.9 (39.7-50.1) 142; 44.4 (40.6-48.2) 55; 46.2 (32.2-60.2) 0.757 0.090
60-90 146; 33.3 (30.6-35.9) 106; 33.1 (29.9-36.3) 40; 33.6 (29.5-37.7)
<60 96; 21.9 (16.3-27.4) 72; 22.5 (18.2-26.8) 24; 20.2 (5.7-34.6)
CKD-EPI (ml/min/1.73 m2) >90 309; 70.4 (64.7-76.0) 243; 75.9 (72.3-79.6) 66; 55.5 (38.4-72.5) 0.242 0.543
60-90 82; 18.7 (13.6-23.7) 48; 15.0 (11.9-18.1) 34; 28.6 (15.2-41.9)
<60 48; 10.9 (5.4-16.4) 29; 9.1 (3.0-15.1) 19; 16.0 (3.9-28.0)
Albuminuria (≥30) and/or eGFR (<60) MDRD 120; 27.3 (20.6-34.5) 96; 30.0 (24.3-35.7) 24; 20.2 (8.3-32.0) 0.162 <0.0001
Albuminuria (≥30) and/or eGFR (<60) CG 157; 35.8 (27.3-44.2) 129; 40.3 (34.5-46.1) 28; 23.5 (7.8-39.3) 0.072 0.022
Albuminuria(≥30) and/or eGFR(<60)CKD-EPI 121; 27.6 (20.6-34.5) 96; 30.0 (24.3-35.7) 25; 21.0 (7.5-34.6) 0.252 <0.0001
CG Cockroft-Gault, CKD-EPI Chronic kidney disease epidemiology collaboration, eGFR Estimated glomerular filtration rate, MDRD Modification of Diet in Renal
Disease, 95 % CI 95 % confidence intervals
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Table 3 Characteristics according to the presence/absence of chronic kidney disease with glomerular filtration rate and albuminuria categories
Variables CKD GFR based CKD stages Albuminuria based CKD stages
No Yes p G1-G2 G3-G4 p A1 A2-A3 p
n (%) 381 (86.8) 58 (13.2) 428 (97.5) 11 (2.5) 386 (87.9) 53 (12.1)
Sex (Men), n; % (95 % CI) 166; 43.6 (36.7-50.5) 19; 32.8 (20.5-45.0) 0.094 185; 43.2 (36.9-49.5) 0 <0.0001 166 (36.2-49.8) 19; 35.8 (23.7-48.0) 0.230
Rural residence, n; % (95 % CI) 275; 72.2 (47.8-96.6) 45; 77.6 (56.7-98.5) 0.432 315; 73.6 (50.2-97.0) 5; 45.5 (0.0-92.3) 0.077 275; 71.2 (46.5-96.0) 45; 84.9 (70.81-99.0) 0.047
Mean age, years (95 % CI) 46.5 (41.5-51.5) 50.2 (46.7-53.8) 0.191 46.9 (42.4-51.5) 50.6 (40.9-60.3) 0.413 46.5 (41.5-51.5) 50.7 (46.8-54.5) 0.193
History of hypertension, n; % (95 % CI) 0.001 0.766 <0.0001
Yes 34; 8.9 (6.1-11.7) 13; 22.4 (12.7-32.1) 42; 9.8 (7.4-12.2) 5; 45.5 (16.6-74.3) 35; 9.1 (6.4-11.7) 12; 22.6 (12.2-33.1)
No 226; 59.3 (49.7-69.0) 21; 36.2 (26.3-46.1) 242; 56.5 (47.0-66.1) 5; 45.5 (17.7-73.2) 230; 59.6 (49.6-69.5) 17; 32.1 (24.0-40.1)
Don’t know 121; 31.8 (21.1-42.4) 24; 41.4 (27.1-55.6) 144; 33.6 (23.0-44.3) 1; 9.1 (0.0-28.2) 121; 31.3 (20.6-42.1) 24; 45.3 (31.4-59.1)
History of diabetes, n; % (95 % CI) 0.017 0.662 0.003
Yes 16; 4.2 (0.9-7.5) 10; 17.2 (6.5-27.9) 23; 5.4 (2.4-8.4) 3; 27.3 (0.0-60.1) 16; 4.1 (0.8-7.5) 10; 18.9 (8.0-29.7)
No 206; 54.1 (40.8-67.3) 20; 48.3 (19.1-49.8) 219; 51.2 (38.2-64.1) 7; 63.6 (28.4-98.8) 211; 54.7 (41.1-68.2) 15; 28.3 (17.1-39.5)
Don’t know 159; 41.7 (29.6-53.9) 28; 48.3 (34.6-61.9) 186; 43.5 (31.9-55.0) 1; 9.1 (0.0-28.2) 159; 41.2 (28.8-53.6) 28; 52.8 (40.1-65.6)
History of gout, n; % (95 % CI) 0.009 0.566 0.0002
Yes 4; 1.0 (0.4-1.7) 1; 1.7 (1.0-2.4) 5; 1.2 (0.6-1.7) 0 4; 1.0 (0.4-1.7) 1; 1.9 (1.2-2.6)
No 169; 44.4 (28.2-60.5) 18; 31.0 (14.9-47.2) 181; 42.3 (26.6-58.0) 6; 54.5 (7.7-100) 174; 45.1 (28.5-61.6) 13; 24.5 (12.9-36.2)
Don’t know 208; 54.6 (38.2-71.0) 39; 67.2 (51.4-83.1) 242; 56.5 (40.7-72.3) 5; 45.5 (0.0-92.3) 208; 53.9 (37.2-70.6) 39; 73.6 (62.1-85.1)
Tobacco use, n; % (95 % CI) 38; 10.0 (8.0-12.0) 3; 5.2 (0.8-9.5) 0.071 41; 9.6 (7.7-11.5) 0 <0.0001 38; 9.8 (7.8-11.9) 3; 5.7 (1.0-10.3) 0.129
Alcohol use, n; % (95 % CI) 231; 60.6 (51.5-69.8) 31; 53.4 (39.5-67.4) 0.310 259; 60.5 (51.9-69.1) 3; 27.3 (0.0-57.0) 0.068 234; 60.6 (51.3-70.0) 28; 52.8 (38.6-67.1) 0.300
Longstanding use of herbal
medicine, n; % (95 % CI)
341; 89.5 (81.5-97.5) 58; 100 (100–100) <0.0001 388; 90.7 (83.4-97.9) 11; 100 (100–100) <0.0001 346; 89.6 (81.8-97.4) 53; 100 (100–100) <0.0001
Longstanding use of street
medications, n; % (95 % CI)
330; 86.6 (81.5-97.5) 54; 93.1 (85.7-100.0) 0.007 373; 87.1 (76.7-97.6) 11; 100 (100–100) <0.0001 335; 86.8 (76.4-97.2) 49; 92.5 (84.1-100.0) 0.025
Mean systolic blood pressure,
mmHg (95 % CI)
118.6 (116.6-120.6) 125.6 (118.3-133.0) 0.053 119.3 (117.1-121.5) 128.3 (103.0-153.5) 0.457 118.5 (116.2-120.7) 127.2 (120.7-133.7) 0.019
Mean diastolic blood pressure,
mmHg (95 % CI)
77.7 (76.8-78.5) 79.8 (76.0-83.5) 0.294 77.9 (76.8-78.9) 81.5 (70.4-92.6) 0.511 77.6 (76.8-78.4) 80.3 (76.8-83.8) 0.164
Any hypertension, n; % (95 % CI) 89; 23.4 (19.7-27.0) 23; 39.7 (31.9-47.4) <0.0001 107; 25.0 (21.7-28.3) 5; 45.5 (16.6-74.3) 0.107 90; 23.3 (19.6-27.0) 22; 41.5 (32.7-50.3) <0.0001
Body mass index≥ 25, n; % (95 % CI) 200; 52.5 (48.7-56.3) 34; 58.6 (48.1-69.2) 0.196 227; 53.0 (48.8-57.3) 7; 63.6 (39.8-100) 0.526 204; 52.8 (49.3-56.4) 30; 56.6 (46.2-67.0) 0.374
Mean fasting glycemia, g/l (SD) 0.91 (0.87-0.94) 1.02 (0.86-1.18) 0.167 0.91 (0.88-0.95) 1.25 (0.73-1.76) 0.200 0.91 (0.87-0.94) 1.02 (0.85-1.20) 0.191
Any diabetes, n; % (95 % CI) 32; 8.4 (4.7-12.1) 11; 19.0 (8.9-29.0) 0.017 40; 9.3 (6.2-12.5) 3; 27.3 (0.0-0.60) 0.102 32; 8.3 (4.6-12.0) 11; 20.8 (10.3-31.2) 0.008












studies performed in SSA and low-to-middle income
countries [8, 9, 19–21]. This result could be related to
the higher prevalence and lower awareness of CKD and
related risk factors observed in this population. Indeed,
we found a high prevalence of CKD risk factors includ-
ing diabetes, hypertension, and longstanding used of
herbal and street medications which have been identified
as predictors of CKD in this setting [9, 11, 20]. These re-
sults support the notion that Africans are at higher risk
of CKD and confirm the high burden of CKD to be a
worldwide phenomenon [3, 4, 22, 23]. However, variable
CKD prevalence estimates have been published de-
pending on the study design and setting, the target
population characteristics, and the CKD definition and
evaluation method [10–12, 24–26]. Compared to urban
settings, CKD seems to be more prevalent in rural areas
despite the lack of statistical difference as noticed in
the metanalysis by Stanifer et al. [9]. The likely high
prevalence observed in rural setting could be related to
the high frequency of well-known clinical and socio-
demographic risk factors for CKD occurrence and pro-
gression to ESRD [13].
In these apparently healthy populations, we observed
that 2.5 % of the participants had CKD stages G3-G4.
Numerous previous studies have reported a much
higher prevalence of decreased eGFR (<60 ml/min/
1.73 m2) based on a single assessment of the kidney
function [8, 12, 19, 21, 24, 26, 27]. The difference would
tend to confirm that studies based upon a single time-
point assessment of kidney function overestimates the
prevalence of CKD in population-based studies. However,
some authors have also reported low prevalence of de-
creased eGFR based on single measurements, which could
reflect true low prevalence, but also issues with the reli-
ability of kidney function measurements including glom-
erular filtration rate estimation equations and the serum
creatinine dosage method used [6, 10, 11].
Based on quantitative estimation of albuminuria, we ob-
served a high prevalence of albuminuria with rural pre-
dominance and rates similar to those observed by Varma
et al. in India using the same method [19]. Most published
studies have reported much higher prevalence of albumin-
uria similar to those observed in our study population
based only on the first measurement [7, 8, 12]. The semi-
Table 4 Predictors of chronic kidney disease and albuminuria in age, sex and residence adjusted logistic regressions
Variables CKD CKD Stages G3-G4 Albuminuria
OR (95 % CI) p OR (95 % CI) p OR (95 % CI) p
Sex (men) 0.63 (0.36-1.08) 0.095 <0.001 (<0.001- < 0.001) <0.0001 0.76 (0.46-1.25) 0.283
Residence (rural) 1.06 (0.52-2.16) 0.880 0.16 (0.04-0.69) 0.008 1.92 (1.06-3.48) 0.031
Age, per years 1.01 (0.99-1.03) 0.178 1.03 (1.00-1.07) 0.066 1.01 (0.99-1.03) 0.293
History of hypertension <0.0001 0.056 <0.0001
No 1 (reference) 1 (reference) 1 (reference)
Yes 3.95 (2.09-7.46) 4.74 (0.84-26.58) 4.67 (2.63-8.29)
Don’t know 2.16 (1.29-3.63) 0.50 (0.03-8.66) 2.38 (1.40-4.03)
History of diabetes <0.0001 0.004 <0.0001
No 1 (reference) 1 (reference) 1 (reference)
Yes 6.64 (2.63-16.75) 4.49 (1.55-13.03) 8.13 (3.17-20.84)
Don’t know 1.89 (1.09-3.26) 0.17 (0.01-3.11) 2.25 (1.26-4.01)
History of gout 0.131 <0.0001 0.064
No 1 (reference) 1 (reference) 1 (reference)
Yes 2.58 (0.96-6.94) <0.001 (<0.001- < 0.001) 3.13 (1.14-8.59)
Don’t know 1.74 (0.94-3.23) 1.38 (0.32-5.94) 2.12 (1.04-4.31)
Tobacco use 0.50 (0.24-1.05) 0.066 <0.001 (<0.001- < 0.001) <0.0001 0.52 (0.25-1.07) 0.077
Alcohol use 0.75 (0.40-1.39) 0.362 0.32 (0.07-1.41) 0.133 0.65 (0.35-1.19) 0.160
Longstanding use of street medications 1.77 (0.87-3.60) 0.113 Few events 1.17 (0.52-2.63) 0.713
Systolic blood pressure, mmHg 1.01 (1.00-1.02) 0.018 1.02 (0.99-1.05) 0.158 1.01 (1.00-1.02) 0.002
Diastolic blood pressure, mmHg 1.01 (0.99-1.03) 0.175 1.02 (0.97-1.08) 0.342 1.01 (1.00-1.03) 0.038
Any hypertension 2.07 (1.38-3.11) 0.0004 2.85 (0.65-12.45) 0.163 2.19 (1.47-3.25) 0.0001
Body mass index ≥ 25 kg/m2 1.34 (0.89-2.02) 0.157 1.55 (0.35-6.83) 0.564 1.22 (0.84-1.78) 0.288
Any diabetes 2.43 (1.15-5.16) 0.021 3.88 (0.75-20.19) 0.107 2.74 (1.26-5.98) 0.011
CKD Chronic kidney disease, GFR glomerular filtration rate (GFR), 95 % CI 95 % confidence intervals
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quantitative dipstick method of albuminuria assessment
without confirmation test, the bias in reading the results
and the presence of transient proteinuria could explain
this high prevalence. Nevertheless, some authors have also
reported low prevalence of albuminuria on dipstick with
prevalence ranging from 2.25 to 7.4 %, which could reflect
true lower risk of albuminuria in their population as well
as bias in reading the results [10, 11, 25, 27].
The reported high prevalence of CKD, stages G3-G4
and albuminuria in our study, driven essentially by hyper-
tension, diabetes, obesity and longstanding used of herbal
and street medications invite policy makers to undertake
an array of actions to promote and sustain nephroprotec-
tion. Such actions could include the implementation of an
integrated CKD prevention and care programmes in order
to promote the screening of high-risk populations, pa-
tient education and creation of multidisciplinary care
teams. The implementation of such programmes has
been shown to significantly reduce mortality, incidence
of end stage renal disease and dialysis, and dialysis re-
lated cost [20].
Strengths and limitations
The present study has some limitations including the non
screening of participants for endemic infections conferring
high risk of CKD such as HIV infection, hepatitis B and C
viral infection; and the non-exhaustive assessment of so-
cioeconomic status which has been shown to be associ-
ated with CKD [9, 21]. Moreover, by conducting this study
in only one geographical site, despite its cosmopolitan
population, there is little opportunity of assessing the vari-
ations in the prevalence of CKD across the country. How-
ever, this study to our knowledge is the first to provide
community-based data on the epidemiology of kidney
disease in the country using the optimal approach to
CKD screening [13]. The inclusion of participants from
a cosmopolite health district including an urban and
rural area likely captures the diversity of the national
population. Another major strength of this study is the
provision of a complete picture of the CKD and albu-
minuria prevalence as well as their determinants in this
population presenting a high prevalence of common
risk factors of CKD.
Conclusion
This study has revealed a high prevalence of CKD, stages
G3-G4 and albuminuria in this setting, driven essentially
by their commonest risk factors, and predominantly in
rural area. These findings invite an array of actions to pro-
mote and sustain preventive measures to lower the risk of
CKD, promote early detection of the disease and imple-
mentation of measures to slow the progression to the ter-
minal stage of the disease.
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